Zusammenfassung
Zytostatika sind wichtige Bausteine für die Krebstherapie. Veränderte Organfunktionen, Komorbiditäten und Begleitmedikationen beeinflussen das Toxizitätsprofil von Zytostatika bei älteren Patienten. Die Studienlage zur Altersspezifität von Zytostatikatoxizität ist limitiert. Ältere Patienten sind in vielen klinischen Studien nicht repräsentativ vertreten. Für die meisten Zytostatika sind bei fehlenden signifikanten Einschränkungen der Organfunktionen keine altersspezifisch erhöhten Toxizitätsraten beschrieben. Letztlich obliegt es der klinischen Erfahrung eines interdisziplinären onkologischen Teams, eine Abwägung zwischen Toxizitätsrisiko mit drohender Lebensqualitätseinschränkung auf der einen und Effektivität einer Zytostatikatherapie auf der anderen Seite vorzunehmen. In diesem Kapitel werden Besonderheiten des geriatrischen Patienten im Hinblick auf die Toxizität von Zytostatika einschließlich moderner zielgerichteter Therapien dargelegt.
Literatur
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32
Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA (2016) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol 34(6):581–587
AGO-Leitlinie. http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/. Zugegriffen am 28.08.2016
Anía BJ, Suman VJ, Fairbanks VF et al (1997) Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 45:825
Balducci L, Corcoran MB (2000) Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 14:193–212
Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M (2015) Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer 51(17):2491–500
Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A positive paper from a SIOG Task Force. Cancer Treat Rev 14:1040
Bokemeyer C, Perry MC (1999) Hepatotoxizität. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin/Heidelberg/New York
van den Brom RRH, van Es SC, Leliveld AM et al (2016) Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treat Rev 46:63–72
Chavez-MacGregor M, Uhang N, Buchholz TA et al (2013) Trastuzumab-realted cardiotoxicity among oder patients with breast cancer. J Clin Oncol 31:4222–4228
Cockroft DW, Galut MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41
Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638–647
Cosmai L, Gallieni M, Porta C (2015) Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol 28(6):647–657
Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300
Dranitsaris G, Lacouture ME (2014) Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast Cancer Res Treat 147(3):631–638
Eisen T, Oudard S, Szczylik C et al (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100:1454–1463
Eklund JW, Trifilio S, Mulcahy MF (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19(8):1057–1063
Elias R, Morales J, Rehman Y, Khurshid H (2016) Immune checkpoint inhibitors in older adults. Curr Oncol Rep 18:47
Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol 23(22):5052–5060
Extermann M, Bonetti M, Sledge GW et al (2004) MAX2 – a convenient index to estimate the average per paitent risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 40(8):1193–1198
Extermann M, Boler I, Reich RR et al (2012) Predicting the risk of chemotherapy toxizity in older patients: the Chemotherapy Risk Assessment Scale for High-age patients (CRASH) score. Cancer 118:3377–3386
Fuchs CS, Moore MR, Harker G et al (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807
Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M (2016) Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma 57:789–796
Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27(2):286–294
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101
Hardy D, Liu CC, Cormier JN et al (2010) Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 21:1825
Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 26:3159
Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J Clin Oncol 34(25):3014–3022
Hulin Ce, Belch A, Shustik C, Petrucci MT, Duehrsen U et al (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. pii: JCO667295. [Epub vor Druck]
Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:2457–3465
Hurria A, Wildes T, Blair SL et al (2014) Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw 12:82–126
Hurria A, Mohile S, Gajra A et al (2016) Validation for a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 34:2366–2371
Hutson TE, Bukowski RM, Rini BI et al (2014) Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 110:1125–1132
Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F et al (2016) Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. doi:10.18632/oncotarget.11657 [Epub vor Druck]
Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK (2016) Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer 122(3):411–419
Kelly CM, Power DG, Lichtman SM (2014) Targeted therapy in older patients with solid tumors. J Clin Oncol 32(24):2635–2646
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 9(7):e101902. doi:10.1371/journal.pone.0101902
Kleeberg UR, Linde H, Günther G, Tessen HW, Kersting M (2016) Bendamustin-rituximab combination is a safe and effective, ambulatory treatment for elderly patients with chronic lymphocytic leukemia: retrospective real-world analysis by age from a German registry and review of the literature. Anticancer Res 36(6):2827–2838
Kumar A, Soares HP, Balducci L et al (2007) Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute sponsored cooperative groups. J Clin Oncol 25:1272
Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26(8):1677–1684
Lichtman SM (2016) Systemic chemotherapy for cancer in elderly persons. www.Uptodate.com. Zugegriffen am 18.10.2016
Lichtman SM, Cirrincione CT, Hurria A et al (2016) Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol 34:699
Lipp HP, Bokemeyer C, Koeppen S (2014) Begleitmaßnahmen bei definierter medikamentöser Therapie: Nephrotoxizität. http://www.onkodin.de/e6/e100876/e100882/. Zugegriffen am 18.10.2016
Loh KP, Janelsins MC, Mohile SG et al (2016) Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol 7:270–280
Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI (2002) Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 50(1):37–45
Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E, ELCAPA Study Group (2016) Optimizing the G8 screening tool for older patients with cancer: diagnostic performance and validation of a six-item version. Oncologist 21(2):188–195
Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76(2):333–338
Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-postivie breast cancer: the cancer and leukemia group B experience. J Clin Oncol 25:3699–3704
Nagele EP, Han M, Acharya NK et al (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8:e60726
NCCN National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Zugegriffen am 19.10.2016
Nishijima TF, Muss HB, Shachar SS, Moschos SJ (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev 45:30–37
Palumbo A, Bringhen S, Mateos MV et al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068–2074
Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26(3):463–476
Pawelec G, Derhovanessian E, Larbi A (2010) Immunosenescence and cancer. Crit Rev Oncol Hematol 75:165–172
Peerzada MM, Spiro TP, Daw H (2010) Pulmonary toxicities of biologics: a review. Anticancer Drugs 21:131–139
Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S (2016) Detection of frailty in elderly cancer patients: improvement of the G8 screening test. J Geriatr Oncol 7(2):99–107
Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A (2015) Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist 20(11):1261–1265
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S et al (2013) Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 13(6):421–432
Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH Jr, Batist G, Wolfson C, Bergman H (2011) Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78(2):138–149
Radermacher J, Bokemeyer C (1999) Renale Toxizität. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie. Springer, Berlin/Heidelberg/New York
Riseberg D (2015) Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol 9:65–73
Sant M, Minicozzi P, Mounier M et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15:931–942
Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097
Schild SE, Stella PJ, Geyer SM et al (2003) The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201
Schütte J, Barth J (2010) Zytostatische Chemotherapie. In: Hiddemann W, Bartram CR (Hrsg) Onkologie. Springer, Berlin, S 401–436
Sioka C, Kyritsis A (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767
Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, de Jongh FE, Braun JJ, Los M, Maartense E, van Tinteren H, Nortier JW, Seynaeve C (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25(3):599–605
Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U (2012) Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 17:838–846
Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H (2015) Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170(2):179–184
Thyss A, Saudes L, Otto J, Creisson A, Gaspard MH, Dassonville O, Schneider M (1994) Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 12(10):2121–2125
Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422
Wedding U (2002) Zytostatische Therapie. In: Höffken K, Kolb G, Wedding U (Hrsg) Geriatrische Onkologie. Springer, Heidelberg, S 244–289
Westfeld M, Liekweg A, Bornemann K, Scharfenberg H, Jaehde U (2006) Manuale zur pharmazeutischen Betreuung, Bd 8, Maligne Erkrankungen. Govi-Verlag, Eschborn
Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32:2595–2603
Yilmaz M, Lahoti A, O’Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894–3904
Yoshida M et al (2016) Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for unfit patients classified by comprehensive geriatric assessment. Eur J Haematol 96(4):409–416
Zaarour M, Weerasinghe C, Nazha B et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor in elderly patients with non-small lung cancer. Expert Rev Anticancer Ther 15(11):1327–1336
Zulman DM, Sussman JB, Chen X et al (2011) Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 26:783–790
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2016 © Springer-Verlag GmbH Deutschland
About this entry
Cite this entry
Schulze-Bergkamen, H. (2016). Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49083-9_6-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-49083-9_6-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49083-9
Online ISBN: 978-3-662-49083-9
eBook Packages: Springer Referenz Medizin